Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade

Abstract Treatment with immune checkpoint inhibitors has altered the course of malignant melanoma, with approximately half of the patients with advanced disease surviving for more than 5 years after diagnosis. Currently, there are no biomarker methods for predicting outcome from immunotherapy. Here,...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ioannis A. Vathiotis, Leonidas Salichos, Sandra Martinez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2022-12-01
Colección:	npj Precision Oncology
Acceso en línea:	https://doi.org/10.1038/s41698-022-00330-3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!